

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Peripheral Thrombus Aspiration Catheter obtained official registration approval by the China NMPA

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 6 November 2023, the Group’s self-developed Peripheral Thrombus Aspiration Catheter, (“**Peripheral Thrombus Aspiration Catheter**” or the “**Product**”) obtained official registration approval by the China National Medical Products Administration (“**NMPA**”). The Product is used for the removal of thrombi from the peripheral arterial and venous system. It is China’s first domestically peripheral thrombus aspiration catheter system with over-the-wire (“**OTW**”) dual lumen technology, which will bring a new treatment option to a large number of peripheral thrombosis patients.

Deep venous thrombosis (“**DVT**”) is one of the most common and challenging peripheral thrombotic diseases in clinical practice. It refers to a clinical syndrome in which blood in deep veins coagulates, forms thrombi, and causes obstruction of blood returning to corresponding blood vessels. When the thrombus breaks off, the embolus can follow the blood flow into the pulmonary artery, causing fatal pulmonary embolism (“**PE**”). The main treatment methods for DVT include anticoagulation, catheter-directed thrombolysis (“**CDT**”), percutaneous mechanical

thrombectomy (“PMT”), and surgical embolectomy, etc. Among them, PMT uses mechanical aspiration and/or catheter aspiration to rapidly remove thrombi, and to restore occluded veins to relieve symptoms of the affected limb. PMT is increasingly recognized by clinical experts.

In response to the huge demand for clinical treatment, the Peripheral Thrombus Aspiration Catheter came into being. The Product consists of an OTW dual-lumen aspiration catheter and a negative pressure aspiration component. The aspiration catheter, in combination with the negative pressure syringe or mechanical negative pressure pump can efficiently aspirate thrombi and embolus in peripheral arteries, veins and filters. The Product can be used in conjunction with the Company’s already marketed product, the vena cava filter, to form a comprehensive solution for the prevention and treatment of lower extremity venous thrombosis, effectively preventing the occurrence of PE while opening the occlusion venous blood vessels. The Product has multiple advantages in clinical application:

The first OTW dual-lumen aspiration catheter in China

The OTW dual lumen is composed of the aspiration lumen and the guidewire lumen. The independent guidewire lumen makes catheter advancement and retraction safer, the clinical operation more convenient, and effectively saves surgical time.

Wedge-shaped aspiration port with double radiopaque marker bands

The double radiopaque marker bands on the distal tip end assist in positioning the direction of the aspiration port to accurately aspirates thrombi. The design of the wedge-shaped aspiration port increases aspiration area on the distal end, effectively aspirates eccentric thrombi, improves aspiration efficiency, and reduces probability of blockage.

Multiple aspiration modes

Compatible with manual aspiration by using a negative pressure syringe or automatic aspiration with mechanical negative pressure pump, and can be flexibly adjusted according to thrombus load to reduce blood loss.

Multiple hardness changes/Hydrophilic coating

The catheter has multiple hardness changes and hydrophilic coating, thus providing better advancement and retraction performance.

Complete specifications and models

The Product has multiple diameters and lengths to comprehensively meet the thrombus removal needs of different vessels.

The Product has been approved for launch, further enriching the Company's product portfolio in the field of peripheral vascular intervention, making it the only domestic enterprise in China that has a product portfolio of both vena cava filters and peripheral thrombus aspiration catheters. In the future, the Company will continue to meet diverse clinical needs through product innovation and technological breakthroughs, and is committed to providing patients with comprehensive device solutions, collaborating with industry experts to promote the research and development and the launch of more clinical urgently needed devices, benefiting more patients.

By order of the Board

LifeTech Scientific Corporation

XIE Yuehui

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 8 November 2023

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.